Provided by Tiger Fintech (Singapore) Pte. Ltd.

Moleculin Biotech

0.6700
-0.0201-2.91%
Post-market: 0.67500.0050+0.75%19:58 EDT
Volume:786.61K
Turnover:527.79K
Market Cap:9.47M
PE:-0.15
High:0.7163
Open:0.6510
Low:0.6270
Close:0.6901
Loading ...

Moleculin Biotech Inc (MBRX) Q4 2024 Earnings Call Highlights: Promising Clinical Trials and ...

GuruFocus.com
·
25 Mar

Q4 2024 Moleculin Biotech Inc Earnings Call

Thomson Reuters StreetEvents
·
25 Mar

Moleculin Biotech Advances Clinical Trials Amid Financial Losses

TIPRANKS
·
25 Mar

Moleculin Biotech Price Target Maintained With a $8.00/Share by HC Wainwright & Co.

Dow Jones
·
25 Mar

Moleculin Biotech Shares Corporate Presentation Update

TIPRANKS
·
24 Mar

Moleculin Biotech FY 2024 GAAP EPS $(6.32) Misses $(3.84) Estimate

Benzinga
·
24 Mar

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
24 Mar

Moleculin Biotech Inc: Initial Data Readout of Phase 3 Miracle Trial Expected in the Second Half of 2025

THOMSON REUTERS
·
24 Mar

Moleculin Biotech Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
22 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
20 Mar

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

GlobeNewswire
·
19 Mar

Moleculin Biotech Inc expected to post a loss of $1.28 a share - Earnings Preview

Reuters
·
19 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
14 Mar

Moleculin to Present at the 37th Annual ROTH Conference

PR Newswire
·
10 Mar

BRIEF-Moleculin Biotech Inc Announces Additional Annamycin Patent Allowances To Enhance Global Exclusivity

Reuters
·
06 Mar

Moleculin Biotech Inc: New Patents Will Extend Coverage to Major Markets Outside U.S.

THOMSON REUTERS
·
06 Mar

Moleculin Biotech Inc: Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

THOMSON REUTERS
·
06 Mar

Moleculin Biotech to be granted new patents for Annamycin

TIPRANKS
·
06 Mar

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

PR Newswire
·
06 Mar

Moleculin Biotech Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
03 Mar